[1]唐　佳　冯龙飞.基于网络药理学和分子对接探讨护肝宁片治疗乙型肝炎的作用机制[J].大众科技,2023,25(8):100-104.
　Exploration on the Mechanism of Huganning Tablets in the Treatment of Hepatitis B Based on Network Pharmacology and Molecular Docking[J].Popular Science & Technology,2023,25(8):100-104.
点击复制

基于网络药理学和分子对接探讨护肝宁片治疗乙型肝炎的作用机制()
分享到：

《大众科技》[ISSN:1008-1151/CN:45-1235/N]

卷:
25
期数:
2023年8
页码:
100-104
栏目:
医药与卫生
出版日期:
2023-08-20

文章信息/Info

Title:
Exploration on the Mechanism of Huganning Tablets in the Treatment of Hepatitis B Based on Network Pharmacology and Molecular Docking
作者:
唐　佳1　冯龙飞2
（1.宜春学院化学与生物工程学院，江西 宜春 336000；2.宜春学院美容医学院，江西 宜春 336000）
关键词:
乙型肝炎; 护肝宁片; 网络药理学; 分子对接
Keywords:
hepatitis B;  huganning tablets;  network pharmacology;  molecular docking
文献标志码:
A
摘要:
目的：通过网络药理学研究护肝宁片治疗乙型肝炎的作用机制。方法：利用TCMSP数据库收集护肝宁片活性成分，构建化合物—靶点图。通过GeneCards和OMIM数据库获取乙型肝炎相关靶点，将护肝宁片活性成分靶点与乙型肝炎疾病靶点取交集，得到关键靶点。通过对共有核心靶点进行蛋白质相互作用分析，分析蛋白相互作用（PPI）中度中心度（DC）、中间性中心性（BC）、紧密性中心性（CC）筛选核心靶基因。选取的护肝宁片主要活性成分与关键靶点进行分子对接。结果：筛选到护肝宁片中木樨草素、槲皮苷、隐丹参酮、丹参酮等81种主要化学成分和198个相关靶点，其中关键靶点有TP53、AKT1、VEGFA、STAT3等。护肝宁片中的活性成分可能通过线粒体、膜筏等细胞组分参与DNA生物合成、细胞凋亡、星形胶质细胞的激活等多种生物学过程，作用通路为乙型肝炎、PI3K-AKT等。分子对接结果显示主要化学成分与核心靶点的结合力均较强，蛋白结晶复合物构象稳定。结论：研究初步表明了护肝宁片通过多成分、多靶点、多通路发挥治疗乙型肝炎的作用机制。
Abstract:
Objective: To study the mechanism of Huganning tablets in the treatment of hepatitis B through network pharmacology. Methods: The active components of Huganing tablets were collected by TCMSP database, and the compound target map was constructed. Hepatitis B related targets were obtained from GeneCards and OMIM databases, and the key targets were obtained by intersection of the active component targets of Huganning tablets and the disease targets of hepatitis B. Protein interaction analysis was performed on shared core targets, and protein interaction (PPI) moderate centrality (DC), intercentrality (BC) and closeness centrality (CC) were analyzed to screen core target genes. The main active ingredients of Huganning tablets were selected for molecular docking with key targets. Results: 81 main chemical components including luteolin, quercetin, cryptotanshinone and tanshinone in Huganning tablets and 198 related targets were screened, among which the key targets were TP53, AKT1, VEGFA, STAT3, etc. The active components in Huganning tablets may participate in DNA biosynthesis, cell apoptosis, astrocyte activation and other biological processes through mitochondria, membrane rafts and other cellular components, and the action pathways are hepatitis B and PI3K-AKT. The results of molecular docking showed that the binding force between the main active components and the core target was strong, and the conformation of the protein crystalline complex was stable. Conclusion: The study preliminarily showed that Huganning tablets play a role in the treatment of hepatitis B through multiple components, multiple targets and multiple pathways.

参考文献/References:

[1] 覃婕，黄万金，王钿，等. 中医药治疗慢性乙型肝炎及相关疾病的研究进展与思考[J]. 河北中医，2021，43(12): 2090-2093，2097.[2] 陈寅萤，王忠，南景一，等. 中医药治疗慢性乙型肝炎的研究进展[J]. 世界中西医结合杂志，2020，15(4): 779-784.[3] 陈皓，徐发飞. 中医治疗慢性乙型病毒性肝炎研究进展[J]. 现代医药卫生，2021，37(24): 4229-4233.[4] 宋建敏. 护肝宁片的临床应用评价[J]. 中国医院用药评价与分析，2013，13(2): 105-107. [5] BOEZIO B, AUDOUZE K, DUCROT P, et al. Network-based approaches in pharmacology[J]. Molecular Informatics, 2017, 36(10): 1700048. [6] 姚雨. 基于深度学习网络的剪接位点及蛋白质相互作用预测方法研究[D]. 合肥: 安徽大学，2019.[7] CHENG Z, SUN G, GUO W, et al. Inhibition of hepatitis B virus replication by quercetin in human hepatoma cell lines[J]. Virologica Sinica, 2015, 30(4): 261-268. [8] PARVEZ M K, AL-DOSARI M S, ARBAB A H, et al. Bioassay-guided isolation of anti-hepatitis B virus flavonoid myricetin-3-O-rhamnoside along with quercetin from Guiera senegalensis leaves[J]. Saudi Pharmaceutical Journal 2020, 28(5): 550-559. [9] MILTONPRAABU S, TOMCZYK M, SKALICKA- WOZNIAK K, et al. Hepatoprotective effect of quercetin: From chemistry to medicine[J].Food and Chemical Toxicology, 2017, 108(Pt B): 365-374. [10] AL-MEGRIN W A, ALKHURIJI A F, YOUSEF A O S, et al. Antagonistic efficacy of luteolin against lead acetate exposure-associated with hepatotoxicity is mediated via antioxidant, anti-inflammatory, and anti-apoptotic activities[J]. Antioxidants, 2019, 9(1): 10. [11] BAI L, NONG Y, SHI Y, et al. Luteolin inhibits hepatitis B virus replication through extracellular signal-regulated kinase-mediated down-regulation of hepatocyte nuclear factor 4α expression[J]. Molecular Pharmaceutics, 2016 , 13(2): 568-577. [12] CHEN W, LU Y, CHEN G, et al. Molecular evidence of cryptotanshinone for treatment and prevention of human cancer[J]. Anti-Cancer Agents in Medicinal Chemistry, 2013, 13(7): 979-987. [13] LI H, GAO C, LIU C, et al. A review of the biological activity and pharmacology of cryptotanshinone, an important active constituent in Danshen[J]. Biomedicine and Pharmacotherapy, 2021, 137: 111332. [14] WANG H, GU J, HOU X, et al. Anti-inflammatory effect of miltirone on inflammatory bowel disease via TLR4/NF-κB/IQGAP2 signaling pathway[J]. Biomedicine and Pharmacotherapy, 2017, 85: 531-540. [15] JIANG Z, GAO W, HUANG L. Tanshinones, critical pharmacological components in Salvia miltiorrhiza[J]. Frontiers in Pharmacology, 2019, 10: 202. [16] CHENX Q . Clinical study of Danshen Injection combined with entecavir in treatment of chronic hepatitis B hepatic fibrosis[J]. Drugs and Clinic, 2016, 11: 1260.[17] YU L, LIU X, HAN C, et al. XRCC1 rs25487 genetic variant and TP53 mutation at codon 249 predict clinical outcomes of hepatitis B virus-related hepatocellular carcinoma after hepatectomy: A cohort study for 10 years’ follow up[J]. Hepatology Research, 2016, 46(8): 765-774. [18] ZHOU H B, HU H P. Challenges in precise treatment for primary liver cancer based on gene mutation[J]. Journal of Clinical Hepatology, 2017, 33(7): 1209-1210.[19] RAWAT S, BOUCHARD M J. The hepatitis B virus (HBV) HBx protein activates AKT to simultaneously regulate HBV replication and hepatocyte survival[J]. Journal of Virology, 2015, 89(2): 999-1012. [20] HOSEL M, QUASDORFF M, RINGELHAN M, et al. Hepatitis B virus activates signal transducer and activator of transcription 3 supporting hepatocyte survival and virus replication[J]. Cellular and Molecular Gastroenterology and Hepatology, 2017, 4(3): 339-363. [21] AMARPURKAR A D, AMARPURKAR D N, VIBHAV S, et al. Angiogenesis in chronic liver disease[J]. Annals of Hepatology, 2007, 6(3): 170-173. [22] YANG J C, TENG C F, WU H C, et al. Enhanced expression of vascular endothelial growth factor-A in ground glass hepatocytes and its implication in hepatitis B virus hepatocarcinogenesis[J]. Hepatology, 2009, 49(6): 1962-1971.[23] YU Z H, CAI M, XIANG J, et al. PI3K/Akt pathway contributes to neuroprotective effect of Tongxinluo against focal cerebral ischemia and reperfusion injury in rats[J]. Journal of Ethnopharmacology, 2016, 181: 8-19. [24] SHI J, ZHENG L, LIN Z, et al. Study of pharmacokinetic profiles and characteristics of active components and their metabolites in rat plasma following oral administration of the water extract of Astragali radix using UPLC-MS/MS[J]. Journal of Ethnopharmacology, 2015, 169: 183-194. [25] COORAY S. The pivotal role of phosphatidylinositol 3-kinase-Akt signal transduction in virus survival[J]. Journal of General Virology, 2004, 85(Pt5): 1065-1076. [26] XIANG K, WANG B. Role of the PI3K?KT?TOR pathway in hepatitis B virus infection and replication[J]. Molecular Medicine Reports 2018, 17(3): 4713-4719.

相似文献/References:

[1]陈松林 黄 燕 冯金鹏 杨 磊.慢性乙型肝炎患者外周血中B7-H3 变化趋势分析[J].大众科技,2019,21(01):20.
　Analysis of B7-H3 Trend in Peripheral Blood of Patients with Chronic Hepatitis B[J].Popular Science & Technology,2019,21(8):20.

备注/Memo

备注/Memo:
【收稿日期】2022-11-11【作者简介】唐佳（1998—），女，湖南邵阳人，宜春学院化学与生物工程学院在读硕士研究生，研究方向为临床药学。【通信作者】冯龙飞（1985—），男，江西万载人，宜春学院美容医学院副教授，博士，从事生命伦理学研究工作。
更新日期/Last Update: 2023-08-24